1. Search Result
Search Result
Results for "

multiple. myeloma

" in MedChemExpress (MCE) Product Catalog:

196

Inhibitors & Agonists

2

Screening Libraries

1

Biochemical Assay Reagents

8

Peptides

35

Inhibitory Antibodies

6

Natural
Products

8

Isotope-Labeled Compounds

4

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-161474

    Drug Isomer Cancer
    Antiproliferative agent-50 (Compd VIII-a) is an inhibitor of myeloma cell proliferation and may be used to inhibit multiple myeloma .
    Antiproliferative agent-50
  • HY-12421

    Epigenetic Reader Domain Cancer
    BET-BAY 002 is a potent BET inhibitor; shows efficacy in a multiple myeloma model.
    BET-BAY 002
  • HY-118266
    BTdCPU
    2 Publications Verification

    Phosphatase Apoptosis Cancer
    BTdCPU is a potent heme regulated inhibitor kinase (HRI) activator that promotes eIF2α phosphorylation and induces apoptosis in Dexamethasone (HY-14648) (Dex)-resistant cancer cells. BTdCPU can be used in the study of cancers such as multiple myeloma and Dex-resistant multiple myeloma .
    BTdCPU
  • HY-100430

    Apoptosis PDI Cancer
    CCF642 is a potent protein disulfide isomerases (PDI) inhibitor with an IC50 of 2.9 μM. CCF642 causes acute endoplasmic reticulum (ER) stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release. CCF642 has broad anti-multiple myeloma activity .
    CCF642
  • HY-142817
    GRK6-IN-2
    1 Publications Verification

    G Protein-coupled Receptor Kinase (GRK) Cancer
    GRK6-IN-2 (compound 10a) is a potent inhibitor of G protein-coupled receptor kinase 6 (GRK6) with an IC50 of 120 nM. GRK6 is a critical kinase required for the survival of multiple myeloma (MM) cells. GRK6-IN-2 has the potential for the research of multiple myeloma .
    GRK6-IN-2
  • HY-157331

    NF-κB Apoptosis Cancer
    DCZ5418 is an inhibitor of TRIP13. DCZ5418 has anti-multiple myeloma activity in vitro and in vivo .
    DCZ5418
  • HY-15994
    Citarinostat
    3 Publications Verification

    ACY241

    HDAC Cancer
    Citarinostat (ACY241) is a second generation potent, orally active and high-selective HDAC6 inhibitor with an IC50 of 2.6 nM (IC50s of 35 nM, 45 nM, 46 nM and 137 nM for HDAC1, HDAC2, HDAC3 and HDAC8, respectively). Citarinostat has anticancer effects .
    Citarinostat
  • HY-P99536

    SL-401

    Interleukin Related Cancer
    Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .
    Tagraxofusp
  • HY-125490

    Debromoshermilamine A

    Others Cancer
    Shermilamine B, a pyridoacridine alkaloid, exhibits potent anticancer activity in multiple myeloma cell lines .
    Shermilamine B
  • HY-149513

    c-Myc Apoptosis Cancer
    EP12 is a c-Myc inhibitor. EP12 is a c-Myc G4 stabilizer. EP12 induces apoptosis and DNA damage in multiple myeloma cells. EP12 disrupts the nuclear translocation of P65/P50 by interfering with the NF-κB signaling pathway. EP12 inhibits multiple myeloma growth .
    EP12
  • HY-P9989

    REGN5458

    CD3 TNF Receptor Cancer
    Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) .
    Linvoseltamab
  • HY-I0466

    Calcium Channel Cardiovascular Disease
    Glutarimide is an important part of many compounds displaying biological activity. Glutarimide is promising for research of anemia, multiple myeloma and cycloheximide .
    Glutarimide
  • HY-P99616

    MOR-202

    CD38 Cancer
    Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research .
    Felzartamab
  • HY-P991295

    C-type Lectin-like Receptors (CTLRs) Cancer
    ABC-015 is a human monoclonal antibody (mAb) targeting KLRG1. ABC-015 can be used in multiple myeloma research.
    ABC-015
  • HY-114340

    Histone Methyltransferase Cancer
    LEM-14 is a potent NSD2 inhibitor with an IC50 of 132 µM. LEM-14 has the potential for the research of multiple myeloma .
    LEM-14
  • HY-138146

    4-oxo Withaferin A

    Drug Derivative Cancer
    4-Dehydrowithaferin A is the analogue of withaferin A. Withaferin A is a withanolide isolated from Withania somnifera. 4-Dehydrowithaferin A has the potential for the research of multiple myeloma .
    4-Dehydrowithaferin A
  • HY-131958

    AMPK Cancer
    D942 is a cell penetrant AMPK activator and partially inhibits the mitochondrial complex I. In multiple myeloma cells, D942 inhibits cell growth .
    D942
  • HY-125939

    Proteasome Cancer
    Bortezomib-pinanediol is a proteasome inhibitor and a prodrug of Bortezomib (HY-10227). Bortezomib-pinanediol inhibits cell growth and can be used for study of multiple myeloma .
    Bortezomib-pinanediol
  • HY-116304
    1G244
    4 Publications Verification

    Dipeptidyl Peptidase Apoptosis Cancer
    1G244 is a potent DPP8/9 inhibitor with IC50s of 12 nM and 84 nM, respectively. 1G244 does not inhibit DPPIV and DPPII. 1G244 induces apoptosis in multiple myeloma cells and has anti-myeloma effects .
    1G244
  • HY-16699
    Nexturastat A
    3 Publications Verification

    HDAC Cancer
    Nexturastat A is a potent, selective HDAC6 inhibitor. Nexturastat A has inhibitory for HDAC6 with an IC50 of 5 nM. Nexturastat A can be used for the research of multiple myeloma (MM) .
    Nexturastat A
  • HY-145428

    Notch γ-secretase Cancer
    BT-GSI is a γ-secretase inhibitor (GSI) and a bone-targeted Notch inhibitor. BT-GSI has dual anti-myeloma and anti-resorptive properties, which can be used for the research of multiple myeloma and associated bone disease. BT-GSI inhibits tumor growth and osteolytic disease progression .
    BT-GSI
  • HY-132971

    Molecular Glues Ligands for E3 Ligase Autophagy Apoptosis Cancer
    Thalidomide-piperazine hydrochloride has the potential for the research of leprosy and multiple myeloma. Thalidomide-piperazine hydrochloride used as a tool in developmental biology leads to important discoveries in the biochemical pathways of limb development .
    Thalidomide-piperazine hydrochloride
  • HY-164385

    mTOR Cancer
    NSC126405 is a mTOR-DEPTOR inhibitor that binds to DEPTOR, prevents mTOR-DEPTOR binding and induces multiple myeloma (MM) cytotoxicity. NSC126405 can be utilized in cancer research .
    NSC126405
  • HY-171498

    Apoptosis Cancer
    gDIS3-13 is an antisense oligonucleotide targeting the DIS3 gene. gDIS3-13 can reduce cell growth and increase apoptosis in multiple myeloma (MM) .
    gDIS3-13
  • HY-160515

    Deubiquitinase Cancer
    USP7-IN-13 (Compound 101) is a USP7 inhibitor with an IC50 value of 0.2-1 μM, which can be used for the study of multiple myeloma .
    USP7-IN-13
  • HY-P991368

    Transmembrane Glycoprotein Cancer
    BSI-046 is a human monoclonal antibody (mAb) targeting SLAMF7/CS1. BSI-046 can be used in Multiple Myeloma research .
    BSI-046
  • HY-P99454

    ABBV-838

    Antibody-Drug Conjugates (ADCs) Cancer
    Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .
    Azintuxizumab vedotin
  • HY-138691B

    JADA82 dihydrochloride; PCK82 dihydrochloride

    Histone Demethylase Cancer
    JQKD82 (JADA82) dihydrochloride is a cell-permeable and selective KDM5 inhibitor. JQKD82 dihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma .
    JQKD82 dihydrochloride
  • HY-138691A

    JADA82 trihydrochloride; PCK82 trihydrochloride

    Histone Demethylase Cancer
    JQKD82 (JADA82) trihydrochloride is a cell-permeable and selective KDM5 inhibitor. JQKD82 trihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma .
    JQKD82 trihydrochloride
  • HY-15901

    mTOR Cancer
    LGB321 is an inhibitor of PIM2-dependent multiple myeloma cell lines, effectively inhibiting proliferation and key signaling pathways such as mTOR-C1 and phosphorylation of BAD .
    LGB321
  • HY-138691

    JADA82; PCK82

    Histone Demethylase Cancer
    JQKD82 (JADA82) is a cell-permeable and selective KDM5 inhibitor. JQKD82 increases H3K4me3 and can be used for the research of multiple myeloma .
    JQKD82
  • HY-120145
    MST-312
    1 Publications Verification

    Telomerase Inhibitor IX

    Telomerase Cancer
    MST-312 is a telomerase inhibitor. MST-312 is a chemically modified derivative of green tea epigallocatechin gallate (EGCG). MST-312 can be used for the research of cancer, such as multiple myeloma (MM) .
    MST-312
  • HY-141687

    CDK Apoptosis Cancer
    NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces apoptosis of multiple myeloma tumors .
    NSC 107512
  • HY-111790
    M3258
    1 Publications Verification

    Proteasome Apoptosis Cancer
    M3258 is an orally bioavailable, potent, reversible and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor. M3258 exerts high biochemical (IC50=3.6 nM) and cellular (IC50=3.4 nM) potency against the LMP7 subunit. M3258 shows strong antitumor efficacy in multiple myeloma xenograft models. M3258 leads to a significant and prolonged suppression of tumor LMP7 activity and ubiquitinated protein turnover and the induction of apoptosis in multiple myeloma cells .
    M3258
  • HY-158197

    Sigma Receptor Proteasome Cancer
    RC-106 is a proteasome inhibitor (IC50: 35 μM) and Sigma receptor modulator with anticancer activity. RC-106 has antiproliferative activity against cancer cells including glioblastoma (GB) and multiple myeloma (MM) .
    RC-106
  • HY-105019A
    Melflufen hydrochloride
    1 Publications Verification

    Melphalan flufenamide hydrochloride

    DNA Alkylator/Crosslinker Apoptosis Cancer
    Melflufen (Melphalan flufenamide) hydrochloride, a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen hydrochloride shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen hydrochloride induces irreversible DNA damage and cytotoxicity in MM cells .
    Melflufen hydrochloride
  • HY-168048

    Proteasome Cancer
    ZINC09518833 is a α-ketoamide nonpeptidic proteasome inhibitor with an IC50 value of 12.4 μM. ZINC09518833 binds both primed and nonprimed sites of the proteasome. ZINC09518833 is promising for research of multiple myeloma (MM) .
    ZINC09518833
  • HY-105019

    Melphalan flufenamide

    DNA Alkylator/Crosslinker Apoptosis Cancer
    Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells .
    Melflufen
  • HY-109109

    CKD-581

    HDAC Apoptosis Cancer
    Alteminostat (CKD-581) is a potent HDAC inhibitor. Alteminostat inhibits the class I-II HDAC family via histone H3 and tubulin acetylation. Alteminostat can be used for lymphoma and multiple myeloma research .
    Alteminostat
  • HY-150105

    BMF-219; Menin-MLL inhibitor 21

    Epigenetic Reader Domain Metabolic Disease Inflammation/Immunology Cancer
    Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes .
    Icovamenib
  • HY-147158

    Molecular Glues Cancer
    ZXH-1-161 is a potent CRBN modulator that selectively induces the degradation of GSPT1 in a CRBN-dependent manner. ZXH-1-161 can inhibit the proliferation of multiple myeloma cells and exhibits antitumor activity .
    ZXH-1-161
  • HY-12863B

    Ligands for Target Protein for PROTAC Epigenetic Reader Domain Cancer
    CPI-0610 carboxylic acid is a ligand for target protein for PROTACT. CPI-0610 carboxylic acid is a potent bromodomain and extra-terminal (BET) protein inhibitor. CPI-0610 carboxylic acid has the potential in the therapy of multiple myeloma .
    CPI-0610 carboxylic acid
  • HY-15163

    TG02; SB1317

    JAK CDK FLT3 Cancer
    Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, JAK2 and FLT3 with IC50 values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma .
    Zotiraciclib
  • HY-119264

    HIF/HIF Prolyl-Hydroxylase Ras Cancer
    PRLX-93936 dihydrochloride (Compound 16) is a HIF-1α inhibitor with anticancer activity. PRLX-93936 can inhibit the activated Ras pathway and can be used in the study of relapsed or refractory multiple myeloma .
    PRLX-93936
  • HY-119264A

    HIF/HIF Prolyl-Hydroxylase Ras Cancer
    PRLX-93936 dihydrochloride (Compound 16) is a HIF-1α inhibitor with anticancer activity. PRLX-93936 can inhibit the activated Ras pathway and can be used in the study of relapsed or refractory multiple myeloma .
    PRLX-93936 dihydrochloride
  • HY-146739

    Epigenetic Reader Domain Cancer
    BRD4 Inhibitor-19 is a BET inhibitor with an IC50 of 55 nM for BRD4-BD1. BRD4 Inhibitor-19 can be used for multiple myeloma research .
    BRD4 Inhibitor-19
  • HY-150586

    HDAC Apoptosis Cancer
    PTG-0861 is a selective histone deacetylase 6 (HDAC6) inhibitor with the IC50 value of 5.92 nM. PTG-0861 induces apoptosis and can be used in the study of acute myeloid leukemia, multiple myeloma and other hematological cancers .
    PTG-0861
  • HY-157216

    HDAC Cancer
    HDAC1 Degrader-1 (compound 1a) is an HDAC1 degrader with anticancer activity. HDAC1 Degrader-1 significantly reduces HDAC1 levels in MM.1S multiple myeloma cells .
    HDAC1 Degrader-1
  • HY-173394

    Carbonic Anhydrase Apoptosis Cancer
    hCAIX/XII-IN-15 (Compound 17β) is an inhibitor of hCA IX and hCA XII, with Kis of 0.42 and 4.37 μM respectively. hCAIX/XII-IN-15 has pro-apoptotic effect in multiple myeloma cells .
    hCAIX/XII-IN-15
  • HY-P991369

    Sialyltransferase Cancer
    EBU-141 is a human monoclonal antibody (mAb) targeting CD75/ST6GAL1. EBU-141 can be used in B-cell lymphoma and multiple myeloma research .
    EBU-141

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: